NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report)'s share price traded up 3.4% on Thursday . The company traded as high as $24.47 and last traded at $24.42. 85,505 shares were traded during mid-day trading, a decline of 83% from the average session volume of 499,608 shares. The stock had previously closed at $23.61.
Wall Street Analysts Forecast Growth
NAMS has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC dropped their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Scotiabank lifted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $43.33.
View Our Latest Stock Analysis on NAMS
NewAmsterdam Pharma Price Performance
The stock's fifty day moving average is $21.77 and its 200-day moving average is $21.04. The stock has a market cap of $2.62 billion, a PE ratio of -9.17 and a beta of -0.04.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.
Insider Activity at NewAmsterdam Pharma
In other news, major shareholder Nap B.V. Forgrowth sold 33,438 shares of the company's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $26.01, for a total transaction of $869,722.38. Following the completion of the transaction, the insider now directly owns 10,727,490 shares of the company's stock, valued at approximately $279,022,014.90. This represents a 0.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 213,284 shares of company stock valued at $4,687,489 over the last 90 days. 19.50% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $50,000. National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in NewAmsterdam Pharma during the 4th quarter worth approximately $80,000. Quarry LP raised its stake in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after buying an additional 6,247 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after buying an additional 7,199 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Stories
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
